Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY WITH RENAL DEPOSITION OF 2,8-DIHYDROXYADENINE LEADING TO NEPHROLITHIASIS AND CHRONIC-RENAL-FAILURE ARCHIVES OF INTERNAL MEDICINE Fye, K. H., Sahota, A., Hancock, D. C., Gelb, A. B., Chen, J., Sparks, J. W., Sibley, R. K., Tischfield, J. A. 1993; 153 (6): 767-770

Abstract

Homozygous adenine phosphoribosyltransferase deficiency is a genetic defect that is associated with 2,8-dihydroxyadenine urolithiasis. Since the prevalence of the heterozygous state is found in 0.4% to 1.2% of the population, it is surprising that more cases of 2,8-dihydroxyadenine urolithiasis have not been reported. Herein we describe a patient with complete adenine phosphoribosyltransferase deficiency with 2,8-dihydroxyadenine urolithiasis leading to chronic renal failure. Gene sequencing revealed that the patient is a compound heterozygote. One of the mutations (a T insertion between bases 346 and 347) has been encountered before, but the second (a G-to-A substitution at base 1356) has not been previously reported. Possible explanations for the unexpected rarity of 2,8-dihydroxyadenine urolithiasis are discussed.

View details for Web of Science ID A1993KR99600011

View details for PubMedID 8447714